Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

Delayed Quote. Delayed  - 08/26 10:01:09 pm
47.18 USD   +0.17%
08/25 BAXTER INTERNAT : and Satellite Healthcare Partner to Bring Innovati..
08/16 BAXTER INTERNAT : to Present at the Morgan Stanely Global Healthcare..
08/15 BAXTER INTERNAT : to Present at the Morgan Stanley Global Healthcare..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL INC
08/25 BAXTER INTERNATIONAL : and Satellite Healthcare Partner to Bring Innovative Dial..
08/16 BAXTER INTERNATIONAL : to Present at the Morgan Stanely Global Healthcare Confer..
08/15 BAXTER INTERNATIONAL INC : Other Events, Financial Statements and Exhibits (form..
08/15 BAXTER INTERNATIONAL : to Present at the Morgan Stanley Global Healthcare Confer..
08/11 BAXTER INTERNATIONAL : Former Gates Foundation and Baxter Executive Peter H. Kho..
08/11 BAXTER INTERNATIONAL : Sigma Spectrum Infusion System Rates Highest in Drug Libr..
08/11 BAXTER INTERNATIONAL : Sigma Spectrum Infusion System Rates Highest in Drug Libr..
08/04 BAXTER : Management's Discussion and Analysis of Financial Condition and Results..
08/04 BAXTER : Presents New Evidence Demonstrating REVACLEAR Dialyzer Associated with ..
08/04 BAXTER : DoseEdge Pharmacy System Identifies Potential Medication Errors for Cli..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Report Its Heart Devices Are Vulnerable to Cyber..
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26DJST JUDE MEDICAL : . Jude Denies Report Its Heart Devices Are Vulnerable to Cyber..
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
08/23 5 Buys From The Narrow-Moat Universe
08/17 IRADIMED : A Niche Medical Device Company With 55%+ Upside Potential
08/17 Tracking David Einhorn's Portfolio - Q2 2016 Update
08/15 Tracking Dan Loeb's Third Point Portfolio - Q2 2016 Update
08/11 Tracking Tweedy Browne Portfolio - Q2 2016 Update
Advertisement
Financials ($)
Sales 2016 10 157 M
EBIT 2016 1 225 M
Net income 2016 2 098 M
Debt 2016 463 M
Yield 2016 0,80%
P/E ratio 2016 11,40
P/E ratio 2017 26,57
EV / Sales 2016 2,57x
EV / Sales 2017 2,47x
Capitalization 25 661 M
More Financials
Chart BAXTER INTERNATIONAL INC
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 50,3 $
Spread / Average Target 6,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
John D. Forsyth Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL I..23.67%25 661
MEDTRONIC PLC12.58%120 679
ZIMMER BIOMET HOLDINGS..26.24%25 904
C R BARD INC14.59%15 945
TERUMO CORP9.16%15 099
DENTSPLY SIRONA INC0.84%14 298
More Results